Gemfeibrozil vs simvastatin in treating diabetic hyperlipidemia and affecting hemorheology

AIM:To compare the effect of gemfeibrozil and simvastatin in treating diabetic hyperlipidemia and affecting hemorheology. METHODS:Thirty six patients(M 16,F 20; age 61 a± s 11 a) received gemfeibrozil 300 mg, po , bid for 45 d and 32 patients (M 13,F 19; age 63 a±10 a) received simvastatin 20 mg po ,qd for 45 d. RESULTS:The total effective rates for reducing total cholesterol (TC) and triglyceride (TG)in gemfeibrozil group and simvastatin group were 56 %,89 % and 72 %,50 % respectively( P 0.05 and P 0.05).The total effective rates for raising high density 1ipoprotein cholesterol (HDL C) in gemfeibrozil group and simvastatin group were 53 %,47 % respectively ( P 0.05).The blood clotting factor Ι. was reduced significantly in gemfeibrozil group treated with gemfeibrozil. No significant adverse reaction was observed in two groups. CONCLUSION:Gemfeibrozil is a good drug in adjusting blood lipid and reducing plasma blood clotting factor Ι. In reducing TG gemfeibrozil is better than simvastatin.